News

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.
The FDA has given full approval to Moderna's COVID-19 shot, Spikevax, allowing it to be used in children 6 months to 11 years old, with some limits on who can get it.